Vimarsana
Biggest News Aggregation in the World

Page 6 - Michael Klichinsky News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Klichinsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Klichinsky Today - Breaking & Trending Today

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages - Vimarsana News

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

Share this article Share this article Allogeneic macrophage therapies may prove successful in providing a solution forged in cell therapy to a broader population of patients, further extending the potential benefits of CARISMA's CAR-Macrophage (CAR-M) platform beyond oncology and into other disease states with unmet clinical needs.   "The collaboration with Dr. Blazar marks the initiation of the development of allogeneic, universal donor derived monocyte and macrophage cell therapies at CARISMA," said Michael Klichinsky, PharmD, PhD, Scientific Co-Founder and Senior Vice President of Researc...

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting - Vimarsana News

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting - First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows significant tumor control, increased survival, and induction of anti-tumor immunity - New ultra-rapid, same-day CAR-monocyte manufacturing process may reduce "vein-to-vein" time News provided by Share this article Share this article PHILADELPHIA, April 9, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immuno...

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies - Vimarsana News

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

Share this article Share this article PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA's total capital raised to nearly $109 million. The funding will be used to advance current pipeline and discovery programs, including the Phase I clinical trial of CARISMA's lead candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted ...

CAR-M: the Super Evolution of Macrophages to Fight Against Tumors - Vimarsana News

CAR-M: the Super Evolution of Macrophages to Fight Against Tumors

Search jobs CAR-M: the Super Evolution of Macrophages to Fight Against Tumors Summary Macrophages are white blood cells that engulf and digest cellular debris, foreign substances, microbes, and cancer cells. Recently, scientists are exploring the method to make macrophage stronger, that is to give it a CAR. These CAR-M cells are expected to efficiently treat tumors. Author Name: Candy Swift Editor: Iris Wang Last Updated: 19-Mar-2021 Macrophages are common phagocytes in...